Portola Pharmaceuticals, Inc.

270 E. Grand Avenue
South San Francisco
United States

Tel: 650.246.7000
Fax: 650.246.7376

Email: contact@portola.com

Show jobs for this employer

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

Stock Exchange: NASDAQ

Stock Symbol: PTLA

LinkedIn  Twitter


269 articles about Portola Pharmaceuticals, Inc.